enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 1. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O podjetju
- Spletna stran
- engene.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sedež
- SAINT-LAURENT, Canada
- Izvršni direktor
- Mr. Ronald H. W. Cooper
- Zaposleni
- 81
- Delnice v obtoku
- 67.02 mio. na dan 2026-09-02
- Prosto prenosljive delnice
- 32.75 mio.
- Tržna kapitalizacija
- 132.02 mio. USD
- Notranje osebe
- 0.11%
- Institucionalni vlagatelji
- 84.11%
- Panoga (SIC)
- Biological Products, (No Diagnostic Substances)
Opis
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Borze in oznake
| Borza | Oznaka | Valuta | Cena | Vrsta |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.745 -3.06% | navadne delnice |
Dividende
Ni bilo najdenih izplačil dividend (preverjeno 08.10.2026). Podjetje verjetno ne izplačuje dividend.
Novice ta teden
Novic s spletnega mesta podjetja še ni.
Največji imetniki
| Imetnik | Delež | Delnice | Datum poročila |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 mio. | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 mio. | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 mio. | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 mio. | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 mio. | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 mio. | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 mio. | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 mio. | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 mio. | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 mio. | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
